Search
Cellectis SA
CLLSAdd to Watchlist
3.300USD
+0.360+12.24%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
235.12MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+12.24%
5 Days
+16.61%
1 Month
+6.80%
6 Months
-31.25%
Year to Date
-31.82%
1 Year
+108.86%
Key Figures
3.310Open
3.390High
32.82KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.05%Turnover Ratio
2.940Prev. Close
3.215Low
90.03KTurnover
LossP/E Static
3.98P/B
0.00%Div Yield TTM
-20.58%ROA
5.48052wk High
2.02Volume Ratio
-36.76MNet Profit
72.34MShares
-0.6698EPS TTM
2.88Beta
-76.34%ROE
1.32752wk Low
5.97%Amplitude
-57.75%Gross Margin
235.12MMarket Cap
-1.16Reward/Risk
4.17%Risk Rate
TradingKey Stock Score of Cellectis SA
Currency: USD Updated: 2026-07-02Key Insights
Cellectis SA's fundamentals are relatively stable, and its growth potential is significant.Its valuation is considered fairly valued, ranking 123 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 7.71.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Cellectis SA's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Cellectis SA Highlights
StrengthsRisks
Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development, and commercialization of rational genome engineering technologies. The Company develops immunotherapies that aim to force the immune system to target and eradicate cancer cells. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction, and biotherapeutics fields. Cellectis SA operates several subsidiaries. The Company operates in France and the United States, among others.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 765.79% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 79.59M.
Undervalued
The company’s latest PE is -4.93, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 12.30M shares, decreasing 31.08% quarter-over-quarter.
Analyst Rating
Based on
7
analysts
Buy
Current Rating
7.714
Target Price
+162.39%
Upside Space
Cellectis SA News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Cellectis SA Info
Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development, and commercialization of rational genome engineering technologies. The Company develops immunotherapies that aim to force the immune system to target and eradicate cancer cells. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction, and biotherapeutics fields. Cellectis SA operates several subsidiaries. The Company operates in France and the United States, among others.
Ticker SymbolCLLS
CompanyCellectis SA
CEOSourdive (David J.D)
Websitehttps://www.cellectis.com/
Related Instruments
+1.62%
+3.50%
+3.96%
+3.72%
+3.31%
+6.14%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of Cellectis SA (CLLS)?
The current price of Cellectis SA (CLLS) is 3.30.
What is the symbol of Cellectis SA?
The ticker symbol of Cellectis SA is CLLS.
What is the 52-week high of Cellectis SA?
The 52-week high of Cellectis SA is 5.48.
What is the 52-week low of Cellectis SA?
The 52-week low of Cellectis SA is 1.33.
What is the market capitalization of Cellectis SA?
The market capitalization of Cellectis SA is 238.72M.
Is Cellectis SA (CLLS) currently rated as Buy, Hold, or Sell?
According to analysts, Cellectis SA (CLLS) has an overall rating of Buy, with a price target of 7.71.
What is the Earnings Per Share (EPS TTM) of Cellectis SA (CLLS)?
The Earnings Per Share (EPS TTM) of Cellectis SA (CLLS) is -0.67.